FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Dan Zimbroff

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Activities & Behaviors

Schizophrenic Psychology

Devices

Placebos

Co-author Network

Publications

TOP 3
Karl Rickels; Sanjay Mathew; Michael D Banov; Dan L Zimbroff; Scott Oshana; Edward Parsons; Stephen R Donahue; Michael Kauffman; Ganesh R Iyer; John F Reinhard
Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial.
Dan L Zimbroff
Pharmacological control of acute agitation: focus on intramuscular preparations.
Dan L Zimbroff; Lewis Warrington; Antony Loebel; Ruoyong Yang; Cynthia O Siu
Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Dan Zimbroff (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: Karl Rickels; Sanjay Mathew; Michael D Banov; Dan L Zimbroff; Scott Oshana; Edward Parsons; Stephen R Donahue; Michael Kauffman; Ganesh R Iyer; John F Reinhard
Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial.
Journal of clinical psychopharmacology 2008;28(2):235-9.
2008: Dan L Zimbroff
Pharmacological control of acute agitation: focus on intramuscular preparations.
CNS drugs 2008;22(3):199-212.
2007: Dan L Zimbroff; Lewis Warrington; Antony Loebel; Ruoyong Yang; Cynthia O Siu
Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study.
International clinical psychopharmacology 2007;22(6):363-70.
2007: David G Daniel; Glenn W Currier; Dan L Zimbroff; Michael Allen; Dan A Oren; George Manos; Robert D McQuade; Andrei Pikalov; David T Crandall
Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
Journal of psychiatric practice 2007;13(3):170-7.
2007: Glenn W Currier; Leslie Citrome; Dan L Zimbroff; Dan A Oren; George Manos; Robert D McQuade; Andrei Pikalov; David T Crandall
Intramuscular aripiprazole in the control of agitation.
Journal of psychiatric practice 2007;13(3):159-69.
2007: Dan L Zimbroff; Ronald N Marcus; George Manos; Elyse Stock; Robert D McQuade; Philippe Auby; Dan A Oren
Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole.
Journal of clinical psychopharmacology 2007;27(2):171-6.
2006: Alan D Feiger; Karl Rickels; Moira Rynn; Dan L Zimbroff; Donald S Robinson
Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.
The Journal of clinical psychiatry 2006;67(9):1354-61.
2005: Dan L Zimbroff; Michael Allen; John Battaglia; Leslie Citrome; Avrim Fishkind; Andrew Francis; Daniel Herr; Douglas Hughes; Marc Martel; Horacio Preval; Ruth Ross
Best clinical practice with ziprasidone IM: update after 2 years of experience.
CNS spectrums 2005;10(9):1-15.
2005: Karl Rickels; Mark H Pollack; Douglas E Feltner; R Bruce Lydiard; Dan L Zimbroff; Robert J Bielski; Kathy Tobias; Jerri D Brock; Gwen L Zornberg; Atul C Pande
Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.
Archives of general psychiatry 2005;62(9):1022-30.
2004: Glenn W Currier; Michael Allen; E Bradshaw Bunney; David G Daniel; Andrew Francis; Andy S Jagoda; Dan L Zimbroff
Standard therapies for acute agitation.
The Journal of emergency medicine 2004;27(4 Suppl):S9-12; quiz S7.
2004: Glenn W Currier; Michael Allen; E Bradshaw Bunney; David G Daniel; Andrew Francis; Andy S Jagoda; Dan L Zimbroff
Intramuscular antipsychotics: clinical experience review.
The Journal of emergency medicine 2004;27(4 Suppl):S3-4; quiz S8.
2004: Glenn W Currier; Michael Allen; E Bradshaw Bunney; David G Daniel; Andrew Francis; Andy S Jagoda; Dan L Zimbroff
Future directions in research.
The Journal of emergency medicine 2004;27(4 Suppl):S27-9.
2004: Glenn W Currier; Michael Allen; E Bradshaw Bunney; David G Daniel; Andrew Francis; Andy S Jagoda; Dan L Zimbroff
Updated treatment algorithm.
The Journal of emergency medicine 2004;27(4 Suppl):S25-6.
2004: Glenn W Currier; Michael Allen; E Bradshaw Bunney; David G Daniel; Andrew Francis; Andy S Jagoda; Dan L Zimbroff
Safety of medications used to treat acute agitation.
The Journal of emergency medicine 2004;27(4 Suppl):S19-24.
2004: Glenn W Currier; Michael Allen; E Bradshaw Bunney; David G Daniel; Andrew Francis; Andy S Jagoda; Dan L Zimbroff
Novel therapies for treating acute agitation.
The Journal of emergency medicine 2004;27(4 Suppl):S13-8.
2004: David G Daniel; Dan L Zimbroff; Rachel H Swift; Edmund P Harrigan
The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy.
International clinical psychopharmacology 2004;19(1):9-15.
2003: Dan L Zimbroff
Management of acute psychosis: from emergency to stabilization.
CNS spectrums 2003;8(11 Suppl 2):10-5.
2003: Atul C Pande; Jerri G Crockatt; Douglas E Feltner; Carol A Janney; Ward T Smith; Richard H Weisler; Peter D Londborg; Robert J Bielski; Dan L Zimbroff; Jonathan R T Davidson; Maria Liu-Dumaw
Pregabalin in generalized anxiety disorder: a placebo-controlled trial.
The American journal of psychiatry 2003;160(3):533-40.
2002: John M Kane; William H Carson; Anutosh R Saha; Robert D McQuade; Gary G Ingenito; Dan L Zimbroff; Mirza W Ali
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
The Journal of clinical psychiatry 2002;63(9):763-71.
2002: Peter Weiden; Naveed Iqbal; Alan Mendelowitz; Rajiv Tandon; Dan L Zimbroff; Ruth Ross
Is switching antipsychotics a good idea for me?
Journal of psychiatric practice 2002;8(2):98.
2002: Peter Weiden; Naveed Iqbal; Alan Mendelowitz; Rajiv Tandon; Dan L Zimbroff; Ruth Ross
Best clinical practice with ziprasidone: update after one year of experience.
Journal of psychiatric practice 2002;8(2):81-97.
1999: David G Daniel; Dan L Zimbroff; S G Potkin; KR Reeves; Edmund P Harrigan; M Lakshminarayanan
Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1999;20(5):491-505.
1997: Dan L Zimbroff; John M Kane; Carol A Tamminga; David G Daniel; RJ Mack; Patricia Wozniak; T B Sebree; B A Wallin; K B Kashkin
Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
The American journal of psychiatry 1997;154(6):782-91.